Vistagen Therapeutics Inc VTGN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2010-10-18 |
| Shares Out. | 41,030,000 |
| Website | vistagen.com/ ↗ |
| Phone | 16505773600 |
| Employees | 41 |
| Revenue | $465,000 |
| Gross Profit | $465,000 |
| Net Income | -$16.3M |
| Free Cash Flow | -$66.6M |
| Total Assets | $48.6M |
| Total Liabilities | $13.0M |
| Equity | $35.5M |
About Vistagen Therapeutics Inc
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Vistagen Therapeutics Inc is a publicly traded company under the ticker symbol VTGN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)